|
|
- Christopher Gaines
- 5 years ago
- Views:
Transcription
1 This is the author version of the paper published as: Author: T.-W. Sun, S.-Y. Zhang and L. Wang Author Address: Title: Plasma B-type natriuretic peptide for early diagnosis of allograft rejection after renal transplantation Year: 2008 Journal: Medical Hypotheses Volume: 70 Issue: 6 Pages: Publisher: ISSN: URL: DOI: Keywords: renal transplantation B-type natriuretic peptide acute allograft renal rejection kidney. Abstract: B-type natriuretic peptides are predominantly synthesized in the ventricular myocytes. This is the response to volume overload or increased stress to the ventricular wall. Plasma B-type natriuretic peptide levels are elevated in patients with chronic renal failure due to reduced glomerular filtration and/or increased myocardial biosynthesis. Allograft renal transplantation significantly reduces plasma B-type natriuretic peptide. Our previous clinical observations have demonstrated that acute allograft renal rejection is associated with a sudden increase in plasma B-type natriuretic peptides. We hypothesized that plasma B-type natriuretic peptide may be used as a sensitive and specific biomarker for clinical diagnosis of acute allograft renal rejection. CSU ID: CSU310514
2 Plasma B-type natriuretic peptide for early diagnosis of allograft rejection after renal transplantation Tong-Wen Sun 1, MD, Shou-Yan Zhang 2, MD, Le-Xin Wang 3, MD, PhD. From: 1. Department of Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou City, Henan Province, China. 2. Tongren Hospital Affiliated to Capital University of Medical Science, Beijing, China. 3. School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, New South Wales, Australia. Short title: BNP and renal transplant Author for correspondence: Professor Lexin Wang, School of Biomedical Sciences, Charles Sturt University, Wagga Wagga, NSW 2678, Australia. Phone: , Fax: , lwang@csu.edu.au Dr Tongwen Sun, Department of Emergency, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, PR China. suntongwen@163.com Word count: 1,694 ABSTRACT B-type natriuretic peptides are predominantly synthesized in the ventricular myocytes. This is the response to volume overload or increased stress to the ventricular wall. Plasma B-type natriuretic peptide levels are elevated in patients with chronic renal failure due to reduced
3 glomerular filtration and/or increased myocardial biosynthesis. Allograft renal transplantation significantly reduces plasma B-type natriuretic peptide. Our previous clinical observations have demonstrated that acute allograft renal rejection is associated with a sudden increase in plasma B-type natriuretic peptides. We hypothesized that plasma B-type natriuretic peptide may be used as a sensitive and specific biomarker for clinical diagnosis of acute allograft renal rejection. Key words: renal transplantation; B-type natriuretic peptide; acute allograft renal rejection; kidney.
4 INTRODUCTION Renal transplantation is one of the most effective treatments for end-stage renal failure. Acute rejection is defined as a sudden deterioration in renal-allograft function. The recipient's immune response to the donor organ is a major risk factor for allograft failure [1, 2]. About 35 percent of allograft recipients have an episode of acute rejection in the first year following transplantation [2]. A needle biopsy of allografts has been used for definitive diagnosis of acute rejection. Needle biopsies are associated with a number of complications, such as hematuria, anuria, perirenal hematoma, bleeding, shock, arteriovenous fistulas, and graft loss [3]. It remains a challenge to develop an accurate and noninvasive diagnostic test for the early diagnosis of allograft rejection. B-type natriuretic peptide (BNP) is a 32-amino acid peptide mainly synthesized by ventricular myocytes in response to increased stress on the ventricular wall (4). BNP has been used for the diagnosis of systolic and diastolic heart failure [5-7] and to predict the short to medium term prognosis of patients with acute coronary syndrome [8, 9]. Plasma BNP levels are also elevated in patients with chronic renal failure; every 10 ml/min reduction in glomerular filtration rate corresponds to about 21% increase in plasma BNP [10]. Elevated BNP in renal failure is often reduced after haemodialysis [11]. Renal transplantation also reduces plasma BNP in patients with chronic renal failure [10]. We hypothesize that the levels of plasma BNP after renal transplantation might be used for clinical diagnosis of posttransplant acute renal rejection. The biosynthesis of BNP B-type natriuretic peptide (BNP) is synthesized as preprobnp mainly in the ventricular myocardium in response to ventricular stretch and pressure overload [1]. PreproBNP is enzymatically cleaved to probnp and released in the form of hormonally active BNP and inactive N-terminal probnp. BNP leads to vasodilatation and natriuresis, which
5 subsequently results in cardiac preload reduction [12]. Elevated plasma BNP concentrations are often seen in patients with left ventricular dysfunction. The plasma levels of BNP correlate well with pulmonary capillary wedge pressure, left ventricular end-diastolic pressure, and left ventricular ejection fraction in patients with systolic or diastolic dysfunction [5-7]. As a result, BNP has become a valuable diagnostic tool for left ventricular dysfunction in acute and primary care settings [5-7]. BNP is metabolized by 3 different mechanisms: binding to natriuretic peptide receptors, cleavage and inactivitation by plasma endopeptidases and clearance by normal glomerular filtration processes [15]. Chronic renal failure and BNP Plasma BNP is also elevated in patients with chronic renal failure [11, 13, 14]. The precise mechanisms for BNP elevation in chronic renal failure are unclear but there may be several explanations. Firstly, sodium and water retention during chronic renal failure may increase the left ventricular end-diastolic volume and wall stress, leading to enhanced biosynthesis and secretion of BNP from ventricular myocytes [10]. Secondly, reduced glomerular filtration rate during chronic renal failure diminishes renal clearance of BNP [10]. Furthermore, the biosynthesis of endopeptidases may be compromised in the presence of renal disease, resulting in decreased degradation of plasma BNP [10]. Several previous studies have shown that renal replacement therapy such as hemodialysis, reduces the levels of plasma BNP [11, 14, 16]. BNP resumes the predialysis level during the dialysis intervals. In our recent studies, progressive reduction in plasma BNP has been found after allograft renal transplantation [17]. For patients who had no acute allograft rejection, plasma BNP levels were more than halved 7 days after the renal transplant and remained low 3 months after the successful transplantation [17].
6 The mechanisms of BNP reduction after renal replacement therapy are complex and not entirely clear. The dialysis-induced BNP reduction may be due to the restoration of normovolemia and reduction in the ventricular overload [16] but BNP can also be filtered out directly from the blood stream. In our study on renal transplantation, there were no significant changes in left ventricular anatomy and function after the surgery [17]. Therefore the BNP reduction was largely due to the improvement of renal function and elimination of BNP. Diagnosis of acute rejection of allograft renal transplantation After renal transplantation, acute allograft dysfunction secondary to acute rejection occurs in around 30-40% of patients [1, 2]. Although in the majority of these patients acute allograft dysfunction is reversible, acute rejection remains a major risk factor for the development of chronic rejection. Histology examination of percutaneous needle biopsy is the most accurate diagnostic tool of acute rejection [18]. It does however, have a number of shortcomings such as undesirable complications. Therefore, there has been active research in recent years to develop less invasive procedures that could diagnose rejection and simultaneously provide mechanistic information on the rejection process [18]. The alternative diagnostic procedures that are currently available include duplex Doppler ultrasound assessment, fine-needle aspiration biopsy, urine cytology, urine cytokine analysis, serum cytokine analysis, and cytokine analysis of biopsy material [18]. Since plasma BNP appears to be very sensitive to the variations in renal function, it might be used as a potential biomarker for acute rejection of renal allograft after transplantation. In a recent small-scale clinical study, we found a substantial reduction in plasma BNP 24 hours following surgery [17]. In patients who experience no clinical symptoms of acute rejection, plasma BNP remains low in the first three months of the operation. However, in patients who
7 had presumptive diagnosis of acute allograft rejection (a more than 25% increase in blood creatinine, fever and/or sudden urine volume reduction), there was a significant rebound in plasma BNP levels at or before blood creatinine elevation [17]. In one patient, BNP rebound was noted 5 days before the occurrence of rejection symptoms, when the blood creatinine remained unchanged [17]. When enhanced immunosuppression was administered to the patients with acute rejection, a rapid reduction of plasma BNP was observed where the decline in creatinine was several days behind the changes in BNP [17]. This data suggests that plasma BNP may be more sensitive than creatinine in reflecting the sudden changes in renal function and may be used as a predictor for acute allograft rejection. In conclusion, non-invasive diagnosis of acute allograft renal rejection remains a challenge. Plasma BNP is elevated in patients with chronic renal failure. Allograft renal transplantation results in a significant reduction in BNP. Preliminary clinical observations have found that acute allograft rejection is associated with a significant resurge of plasma BNP, even several days before the increase in blood creatinine. It is likely that BNP, in particular N-terminal probnp which is predominantly eliminated by glomerular filtration, may serve as a sensitive and specific biomarker for acute rejection. Large-scale clinical studies are required to test this hypothesis.
8 REFERENCES 1. Lindholm A, Ohlman S, Albrechtsen D, Tufveson G, Persson H, Persson NH. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56: Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to N Engl J Med 2000; 342: Benfield MR, Herrin J, Feld L, Rose S, Stablein D, Tejani A. Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation 1999; 67: Nakamura S, Naruse M, Naruse K, et al. Atrial natriuretic peptide and brain natriuretic peptide coexist in the secretory granules of human cardiac myocytes. Am J Hypertens 1991; 4: Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: Wei TM, Zeng CL, Chen LP, et al. Bedside test of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in patients with hypertension. Eur J Heart Fail 2005; 7: de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 2001; 345: Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/ non-st - elevation myocardial infarction. J Am Coll Cardiol 2003; 41:
9 9. Sun TW, Wang LX, Zhang YZ. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. Arch Med Res 2006; 37: Horl WH. Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Invest Med 2005; 53: Zeng C, Wei T, Jin L, Wang L. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J 2006; 36: Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339: Corboy JC, Walker RJ, Simmonds MB, Wilkins GT, Richards AM, Espiner EA. Plasma natriuretic peptides and cardiac volume during acute changes in intravascular volume in haemodialysis patients. Clin Sci 1994; 87: Vesely DL. Natriuretic peptides and acute renal failure. Am J Physiol - Renal Physiol 2003; 285:F Kone BC. Molecular biology of natriuretic peptides and nitric oxide synthases. Cardiovasc. Res. 2001; 51: Wahl HG, Graf S, Renz H, Fassbinder W. Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal probnp by hemodialysis. Clin Chem 2004; 50: Wei TM, Jin L, Lu LC, Zhang BJ, Wang LX. Changes in plasma B-type natriuretic peptide after allograft renal transplantation. Nephrology 2007; 12: Chandraker A. Diagnostic techniques in the work-up of renal allograft dysfunction-an update. Curr Opin Nephrol Hypertens 1999; 8:
Effect of Short-term Maximal Exercise on BNP Plasma Levels in. Healthy Individuals
1 Effect of Short-term Maximal Exercise on BNP Plasma Levels in Healthy Individuals Jan Krupicka, MD, Tomas Janota, MD, Zdislava Kasalova, MD, Jaromir Hradec, MD 3rd Department of Internal Medicine, 1st
More informationBNP as a Predictor of Cardiovascular Disease and All Cause Mortality. Dr. Thierry Le Jemtel
BNP as a Predictor of Cardiovascular Disease and All Cause Mortality Dr. Thierry Le Jemtel Outline Role of BNP and probnp as relevant biomarkers in cardiac conditions Role of BNP and probnp as relevant
More informationΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος Τούσουλης ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationEffect of an increase in coronary perfusion on transmural. ventricular repolarization
Effect of an increase in coronary perfusion on transmural ventricular repolarization Yan-Zhou Zhang 1, MD, PhD, Ben He 1, MD, Le-Xin Wang 2, MD, PhD. From: 1 Department of Cardiology, Renji Hospital, Medical
More informationEffect of an Increase in Coronary Perfusion on Transmural Ventricular Repolarization
Physiol. Res. 56: 285-290, 2007 Effect of an Increase in Coronary Perfusion on Transmural Ventricular Repolarization Y.-Z. ZHANG 1, B. HE 1, L.-X. WANG 2 1 Department of Cardiology, Renji Hospital, Medical
More informationPaul M McKie, Alessandro Cataliotti, Guido Boerrigter, Horng C Chen, Fernando L Martin, and John C Burnett Jr
Cardiorenal Enhancing and Aldosterone Suppressing Actions of a Novel Designer Natriuretic Peptide in Experimental Hypertension with Ventricular Pressure Overload Paul M McKie, Alessandro Cataliotti, Guido
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Clinical perspective It was recently discovered that small RNAs, called micrornas, circulate freely and stably in human plasma. This finding has sparked interest in the potential
More informationThe Who, How and When of Advanced Heart Failure Therapies. Disclosures. What is Advanced Heart Failure?
The Who, How and When of Advanced Heart Failure Therapies 9 th Annual Dartmouth Conference on Advances in Heart Failure Therapies Dartmouth-Hitchcock Medical Center Lebanon, NH May 20, 2013 Joseph G. Rogers,
More informationClinical efficacy of ultrafiltration in the treatment of acute decompensated heart failure with diuretic resistance.
Biomedical Research 2017; 28 (14): 6155-6159 ISSN 0970-938X www.biomedres.info Clinical efficacy of ultrafiltration in the of acute decompensated heart failure with diuretic resistance. Jian Zhang, Qi
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationPearls in Acute Heart Failure Management
Pearls in Acute Heart Failure Management Best Practices Juan M. Aranda Jr., M.D. Professor of Medicine Medical Director of Heart Failure/ Transplant Program University of Florida College of Medicine Disclosures:
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationIs B-type natriuretic peptide a risk factor for heart failure in patients treated with bardoxolone methyl?
University of Wollongong Research Online Illawarra Health and Medical Research Institute Faculty of Science, Medicine and Health 2015 Is B-type natriuretic peptide a risk factor for heart failure in patients
More informationNT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure
Reference Section NT-proBNP A New Test for Diagnosis, Prognosis and Management of Congestive Heart Failure a report by Drs Rahul Sakhuja and James L Januzzi Cardiology Division and Department of Medicine,
More informationAustralian Journal of Basic and Applied Sciences, 9(36) December 2015, Pages: ISSN: Journal home page:
ISSN:1991-8178 Australian Journal of Basic and Applied Sciences Journal home page: www.ajbasweb.com Role of Biochemical Tests Artery Disease (ANP, BNP) in the Evaluation of Patients with Coronary 1 Saad
More informationEchocardiography analysis in renal transplant recipients
Original Research Article Echocardiography analysis in renal transplant recipients S.A.K. Noor Mohamed 1*, Edwin Fernando 2, 1 Assistant Professor, 2 Professor Department of Nephrology, Govt. Stanley Medical
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationDuring exercise the heart rate is 190 bpm and the stroke volume is 115 ml/beat. What is the cardiac output?
The Cardiovascular System Part III: Heart Outline of class lecture After studying part I of this chapter you should be able to: 1. Be able to calculate cardiac output (CO) be able to define heart rate
More informationTo estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome
Original Research Article To estimate the serum level of N-terminal pro-brain natriuretic peptide levels in acute coronary syndrome Mohamed Yasar Arafath 1, K. Babu Raj 2* 1 First Year Post Graduate, 2
More informationPrediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring
Prediction of Life-Threatening Arrhythmia in Patients after Myocardial Infarction by Late Potentials, Ejection Fraction and Holter Monitoring Yu-Zhen ZHANG, M.D.,* Shi-Wen WANG, M.D.,* Da-Yi Hu, M.D.,**
More informationPerformance and Quality Measures 1. NQF Measure Number. Coronary Artery Disease Measure Set
Unless indicated, the PINNACLE Registry measures are endorsed by the American College of Cardiology Foundation and the American Heart Association and may be used for purposes of health care insurance payer
More informationLeft ventricular hypertrophy: why does it happen?
Nephrol Dial Transplant (2003) 18 [Suppl 8]: viii2 viii6 DOI: 10.1093/ndt/gfg1083 Left ventricular hypertrophy: why does it happen? Gerard M. London Department of Nephrology and Dialysis, Manhes Hospital,
More informationDoppler ultrasound, see Ultrasonography. Magnetic resonance imaging (MRI), kidney oxygenation assessment 75
Subject Index Acidemia, cardiorenal syndrome type 3 146 Acute Dialysis Quality Initiative (ADQI) acute kidney injury biomarkers, see Acute kidney injury; specific biomarkers cardiorenal syndrome, see specific
More informationCorrelations among copeptin, ischemia-modified albumin, and the extent of myocardial injury in patients with acute carbon monoxide poisoning
Correlations among copeptin, ischemia-modified albumin, and the extent of myocardial injury in patients with acute carbon monoxide poisoning J. Li, J.S. Wang, Z.X. Xie, W.Z. Wang, L. Wang, G.Y. Ma, Y.Q.
More informationΟΙ ΒΙΟΔΕΙΚΤΕΣ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ. Καθηγητής Καρδιολογίας
ΕΘΝΙΚΟ ΚΑΙ ΚΑΠΟΔΙΣΤΡΙΑΚΟ ΠΑΝΕΠΙΣΤΗΜΙΟ ΑΘΗΝΩΝ ΙΑΤΡΙΚΗ ΣΧΟΛΗ Ά ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ Διευθυντής: Καθηγητής Δημήτριος ΤΟΥΣΟΥΛΗΣ ΟΙ ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΟΛΟΓΙΑ ΣΗΜΕΡΑ ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationIndications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014
Indications of Coronary Angiography Dr. Shaheer K. George, M.D Faculty of Medicine, Mansoura University 2014 Indications for cardiac catheterization Before a decision to perform an invasive procedure such
More informationKrediet slide di 18
1 di 18 Assessment of fluid status in PD patients Raymond T. Krediet, Amsterdam, Netherlands Chairs:Walther H. Boer, Utrecht, The Netherlands F. Fevzi Ersoy, Antalya, Turkey Prof. Raymond T. Krediet DDivision
More informationThis article is downloaded from.
This article is downloaded from http://researchoutput.csu.edu.au It is the paper published as: Author: G.-Y. Li, J.-Z. Liu, S.-G. Chen, C.-B. Wang, B. Zhang and L. Wang Title: Effect of a seashell protein
More informationProtocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year
PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart
More informationCharacteristics of Patients Initializing Peritoneal Dialysis Treatment From 2007 to 2014 Analysis From Henan Peritoneal Dialysis Registry data
DIALYSIS Characteristics of Patients Initializing Peritoneal Dialysis Treatment From 7 to 14 Analysis From Henan Peritoneal Dialysis Registry data Xiaoxue Zhang, 1 Ying Chen, 1,2 Yamei Cai, 1 Xing Tian,
More informationAtrial natriuretic peptide (ANP) and brain natriuretic
Exertional Changes in Circulating Cardiac Natriuretic Peptides in Patients with Suggested Coronary Artery Disease Sébastien Bergeron, MD, Jacob E. Møller, MD, PhD, Kent R. Bailey, PhD, Horng H. Chen, MD,
More informationLnformation Coverage Guidance
Lnformation Coverage Guidance Coverage Indications, Limitations, and/or Medical Necessity Abstract: B-type natriuretic peptide (BNP) is a cardiac neurohormone produced mainly in the left ventricle. It
More informationNew PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0.
New PINNACLE Measures The below measures for PINNACLE will be added as new measures to the outcomes reporting starting with Version 2.0. Measure Steward Measure Name Measure Description Rationale for Adding
More informationPostoperative monitoring after
Postoperative monitoring after kidney transplantation Bundit sakulchairungrueng,md Vascular and Transplantation Unit Faculty of Medicine Ramathibodi Hospital Mahidol University Reference Introduction A
More informationRisk Stratification in Heart Failure: The Role of Emerging Biomarkers
Risk Stratification in Heart Failure: The Role of Emerging Biomarkers David G. Grenache, PhD Associate Professor of Pathology, University of Utah Medical Director, ARUP Laboratories Salt Lake City, UT
More informationNT-proBNP: Evidence-based application in primary care
NT-proBNP: Evidence-based application in primary care Associate Professor Rob Doughty The University of Auckland, Auckland City Hospital, Auckland Heart Group NT-proBNP: Evidence in Primary Care The problem
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care. Md. Shahidul Islam, M.D., Ph.D
ESCBM meeting 2018, Prague Utility of Cardiac Biomarkers in Clinical Heart Failure Care Md. Shahidul Islam, M.D., Ph.D shaisl@me.com 2 3 Circulating Biomarkers in Heart Failure. Berezin AE. Adv. Exp. Med.
More informationCURRICULUM VITAE July 5, Name Chang-Kwon Oh. Date of Birth August 15, 1961
CURRICULUM VITAE July 5, 2014 Name Chang-Kwon Oh Date of Birth August 15, 1961 Present Academic & Hospital Appointment Professor, Department of Surgery Ajou University, School of Medicine Chief, Department
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationCOMPLETE INHIBITION OF RENAL RESERVE IN CHRONIC RENAL FAILURE BY A COMBINATION OF ACEI AND ARB
COMPLETE INHIBITION OF RENAL RESERVE IN CHRONIC RENAL FAILURE BY A COMBINATION OF ACEI AND ARB CG Musso ¹, J Reynaldi¹, N Imperiali ¹, L Algranati ¹, DG Oreopoulos ² Nephrology Department Hospital Italiano
More informationMeasuring Natriuretic Peptides in Acute Coronary Syndromes
Measuring Natriuretic Peptides in Acute Coronary Syndromes Peter A. McCullough, MD, MPH, FACC, FACP, FAHA, FCCP Consultant Cardiologist Chief Academic and Scientific Officer St. John Providence Health
More informationHeart failure (HF) is a complex clinical syndrome that results in the. impairment of the heart s ability to fill or to pump out blood.
Introduction: Heart failure (HF) is a complex clinical syndrome that results in the impairment of the heart s ability to fill or to pump out blood. As of 2013, an estimated 5.8 million people in the United
More informationBiomarkers in Acute Cardiac Disease Samir Arnaout, M.D.FESC Associate Professor of Medicine Internal Medicine i & Cardiology American University of Beirut Time course of the appearance of various markers
More informationPatient Education. Transplant Services. Benefits and. Of a kidney/pancreas transplant
Patient Education Benefits and Risks Of a kidney/pancreas transplant This chapter discusses the benefits as well as the risks of a kidney and/or pancreas transplant. The complications of transplant and
More informationThe study of brain natriuretic peptide level and heart rate turbulence in acute coronary syndrome
International Research Journal of Public and Environmental Health Vol.3 (12),pp. 293-298, December 2016 Available online at http://www.journalissues.org/irjpeh/ http://dx.doi.org/10.15739/irjpeh.16.036
More informationDOWNLOAD PDF ABC OF HEART FAILURE
Chapter 1 : The ABCs of managing systolic heart failure: Past, present, and future Heart failure is a multisystem disorder which is characterised by abnormalities of cardiac, skeletal muscle, and renal
More informationCardiovascular Disease in CKD. Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center
Cardiovascular Disease in CKD Parham Eftekhari, D.O., M.Sc. Assistant Clinical Professor Medicine NSUCOM / Broward General Medical Center Objectives Describe prevalence for cardiovascular disease in CKD
More informationThe Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio
Clinical Chemistry / Renal Function and BNP and NT-proBNP The Effect of Renal Dysfunction on BNP, NT-proBNP, and Their Ratio Pornpen Srisawasdi, PhD, 1 Somlak Vanavanan, MSc, 1 Charaslak Charoenpanichkit,
More informationMedical Management of Acute Heart Failure
Critical Care Medicine and Trauma Medical Management of Acute Heart Failure Mary O. Gray, MD, FAHA Associate Professor of Medicine University of California, San Francisco Staff Cardiologist and Training
More informationΟξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών;
Οξεία καρδιακή ανεπάρκεια: Ποιες παράμετροι συμβάλλουν στη διαστρωμάτωση κινδύνου των ασθενών; Γ. Φιλιππάτος, MD, FACC, FESC, FCCP Επ. Καθηγητής Καρδιολογίας Πανεπ. Αθηνών Clinical Outcomes in Patients
More informationCopyright 2011, 2007 by Mosby, Inc., an affiliate of Elsevier Inc. Normal Cardiac Anatomy
Mosby,, an affiliate of Elsevier Normal Cardiac Anatomy Impaired cardiac pumping Results in vasoconstriction & fluid retention Characterized by ventricular dysfunction, reduced exercise tolerance, diminished
More informationRevascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing
Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine
More informationCardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology
Cardiorenal Syndrome Prof. Dr. Bülent ALTUN Hacettepe University Faculty of Medicine Department of Internal Medicine Division of Nephrology Heart and Kidney The kidney yin dominates water, The heart yang
More informationDiagnosis is it really Heart Failure?
ESC Congress Munich - 25-29 August 2012 Heart Failure with Preserved Ejection Fraction From Bench to Bedside Diagnosis is it really Heart Failure? Prof. Burkert Pieske Department of Cardiology Med.University
More informationB-type Natriuretic Peptide in VHD: a Non-imaging Helper for the Cardiologist. Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM
B-type Natriuretic Peptide in VHD: a Non-imaging Helper for the Cardiologist Dr. Julien Magne, PhD Sart Tilman Liège, BELGIUM Conflict of Interest Disclosure None BNP Molecular Forms and Processing Brain
More informationNew Trials. Iain Squire. Professor of Cardiovascular Medicine University of Leicester. Chair, BSH
New Trials Iain Squire Professor of Cardiovascular Medicine University of Leicester Chair, BSH BSH Heart Failure Day for Revalidation and Training 2017 Presentation title: New Trials Speaker: Iain Squire
More information4/6/2017. Singapore? CKiD IPPN. Understanding pediatric CKD A Global Effort
Biomarker mid-region pro-adrenomedullin is associated with diastolic dysfunction in children with end-stage renal failure Sharon Teo, Kar-Hui Ng, M Than, L Gong, JB Lunaria, TH Heng, C Chan, YWP Lau, WS
More informationHeart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017
Heart Transplantation ACC Middle East Conference Dubai UAE October 21, 2017 Randall C Starling MD MPH FACC FAHA FESC FHFSA Professor of Medicine Kaufman Center for Heart Failure Department of Cardiovascular
More informationOUT OF DATE. Choice of calcineurin inhibitors in adult renal transplantation: Effects on transplant outcomes
nep_734.fm Page 88 Friday, January 26, 2007 6:47 PM Blackwell Publishing AsiaMelbourne, AustraliaNEPNephrology1320-5358 2006 The Author; Journal compilation 2006 Asian Pacific Society of Nephrology? 200712S18897MiscellaneousCalcineurin
More informationChapter 4: Cardiovascular Disease in Patients With CKD
Chapter 4: Cardiovascular Disease in Patients With CKD The prevalence of cardiovascular disease is 68.8% among patients aged 66 and older who have CKD, compared to 34.1% among those who do not have CKD
More informationRecent literature highlights the high negative
Cost-effectiveness and budget impact analysis of natriuretic peptide testing in the diagnosis of chronic heart failure Heart failure (HF) is a major reason for hospitalization and represents a huge cost
More informationLCD Information Document Information LCD ID Number L30046
Local Coverage Determination (LCD): Pathology and Laboratory: B-type Natriuretic Peptide (BNP) Testing (L30046) LCD Information Document Information LCD ID Number L30046 LCD Title Pathology and Laboratory:
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationRENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein
RENAL TRANSPLANT PATIENTS WITH HIGH-FLOW AVF: WHEN & HOW TO INTERVENE Stuart Greenstein, MD Abdominal Organ Transplant Division Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY
More information1. Prevalence and prognostic significance of incidental cardiac troponin T elevation in ambulatory patients with stable coronary artery disease: data from the Heart and Soul study Hsieh, B.P., et al. Am
More informationWHAT S NEW IN HEART FAILURE
WHAT S NEW IN HEART FAILURE Drugs, Devices and Diagnostics John M. Herre, MD, FACC, FACP Director, Advanced Heart Failure Program Sentara Helathcare Professor of Medicine Eastern Virginia Medical School
More informationCopeptin in heart failure: Associations with clinical characteristics and prognosis
Copeptin in heart failure: Associations with clinical characteristics and prognosis D. Berliner, N. Deubner, W. Fenske, S. Brenner, G. Güder, B. Allolio, R. Jahns, G. Ertl, CE. Angermann, S. Störk for
More informationBiomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018
Biomarkers in cardiovascular disease Felix J. Rogers, DO, FACOI April 29, 2018 Biomarkers NIH: A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological
More informationTreating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment
ESC 2012 27Aug - 3Sep, 2012, Munich, Germany Treating the patient with acute heart failure. What do we really know? Principles of acute heart failure treatment Marco Metra, MD, FESC Cardiology University
More informationChina Academic Journal Electronic Publishing House. All rights reserved.
2006598617 NatlMed J China,May 9, 2006, Vol 86, No117 1165 B B(BNP) 243 111,BNP (LVEF) 40% ( n = 111)> 40%( n = 132) ;(NYHA, n = 110) (NYHA, n = 133) BNP, BNP(29210 ng/l vs 1719 ng/l, P < 01001), LVEF40%
More informationEDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE
EDUCATIONAL COMMENTARY CARDIAC FUNCTION: BIOCHEMICAL MARKERS UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE
More informationWithin-Home Blood Pressure Variability on a Single Occasion Has Clinical Significance
Published online: May 12, 2016 2235 8676/16/0041 0038$39.50/0 Mini-Review Within-Home Blood Pressure Variability on a Single Occasion Has Seiichi Shibasaki a, b Satoshi Hoshide b Kazuomi Kario b a Department
More informationNatriuretic Peptides The Cardiologists View. Christopher defilippi, MD University of Maryland Baltimore, MD, USA
Natriuretic Peptides The Cardiologists View Christopher defilippi, MD University of Maryland Baltimore, MD, USA Disclosures Research support: Alere, BG Medicine, Critical Diagnostics, Roche Diagnostics,
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationBlood Pressure Regulation 2. Faisal I. Mohammed, MD,PhD
Blood Pressure Regulation 2 Faisal I. Mohammed, MD,PhD 1 Objectives Outline the intermediate term and long term regulators of ABP. Describe the role of Epinephrine, Antidiuretic hormone (ADH), Renin-Angiotensin-Aldosterone
More informationClinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients
Original Research Article Clinical Outcomes of Renal Transplantation in Hepatitis C Virus Positive Recipients Surendran Sujit 1*, N. Gopalakrishnan 2 1 Assistant Professor, 2 Professor and Head Department
More informationΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ
ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ ΚΑΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΛΔΟΣΤΕΡΟΝΗΣ ΣΠΥΡΟΜΗΤΡΟΣ ΓΕΩΡΓΙΟΣ MD, FESC. E.Α Κ/Δ Γ.Ν.ΚΑΤΕΡΙΝΗΣ Aldosterone is a mineralocorticoid hormone synthesized by the adrenal glands that has several regulatory
More informationBiomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D.
Biomarkers and Arrhythmias/Devices Ulrika Birgersdotter-Green, M.D. Professor of Medicine Division of Cardiology University of California, San Diego Disclosures Honoraria, Research Grants, Medtronic Honoraria,
More informationHeart Failure in Women: Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre
Heart Failure in Women: More than EF? Dr Goh Ping Ping Cardiologist Asian Heart & Vascular Centre Overview Review pathophysiology as it relates to diagnosis and management Rational approach to workup:
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationUniversity of Groningen. BNP and NT-proBNP in heart failure Hogenhuis, Jochem
University of Groningen BNP and NT-proBNP in heart failure Hogenhuis, Jochem IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationEarly diagnosis of rats with acute myocardial infarction by measurement of brain natriuretic peptide
EXPERIMENTAL AND THERAPEUTIC MEDICINE 5: 1201-1205, 2013 Early diagnosis of rats with acute myocardial infarction by measurement of brain natriuretic peptide JIAN LI, FANG-FANG YIN and YING-LONG HOU Department
More informationAcute cardiogenic shock with standing-still heart
Acute cardiogenic shock with standing-still heart Ga Yeon Lee April, 21, 2017 Division of cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Seoul, South Korea
More informationAcute Changes in Circulating Natriuretic Peptide Levels in Relation to Myocardial Ischemia
Journal of the American College of Cardiology Vol. 44, No. 10, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.07.057
More informationSummary Protocol ISRCTN / NCT REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6
Summary Protocol REVIVED-BCIS2 Summary protocol version 4, May 2015 Page 1 of 6 Background: Epidemiology In 2002, it was estimated that approximately 900,000 individuals in the United Kingdom had a diagnosis
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure Treatment In Patients With Recurrent Myocardial Infarction
Received: 10-01-2013 Accepted: 19-02-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 1 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION
More informationMyocarditis in Infants and Children
in Infants and Children Guideline of the German Society of Pediatric Cardiology Thomas Paul, Carsten Tschöpe, Reinhard Kandolf Children s Heart Center, Georg-August-University, Göttingen Department of
More informationA study of Brain Natriuretic Peptide levels in acute cardiac failure
Original Research Article A study of Brain Natriuretic Peptide levels in acute cardiac failure Bhavik Prajapati 1*, Anirudh Kulkarni 2 1 Assistant Professor, Department of Medicine, SMS Multispecialty
More informationValue of echocardiography in chronic dyspnea
Value of echocardiography in chronic dyspnea Jahrestagung Schweizerische Gesellschaft für /Schweizerische Gesellschaft für Pneumologie B. Kaufmann 16.06.2016 Chronic dyspnea Shortness of breath lasting
More informationThe importance of left atrium in LV diastolic function
II Baltic Heart Failure Meeting and Congress of Latvian Society of Cardiology The importance of left atrium in LV diastolic function Dr. Artem Kalinin Eastern Clinical University Hospital Riga 30.09.2010.
More informationNGAL Connect to the kidneys
NGAL Connect to the kidneys Acute kidney injury (AKI) An imposing medical and diagnostic challenge >13 million AKI patients each year ~ 30% with fatal outcome Cardiac surgery > 1 million patients/year
More informationAtrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction
Atrial dyssynchrony syndrome: An overlooked cause of heart failure with normal ejection fraction JC Eicher, G Laurent, O Barthez, A Mathé, G Bertaux, JE Wolf Heart Failure Treatment Unit, Rhythmology and
More informationFluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)
Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI) Robert W. Schrier, MD University of Colorado School of Medicine Denver, Colorado USA Prevalence of acute renal failure in Intensive
More informationDr. Mehmet Kanbay Department of Medicine Division of Nephrology Istanbul Medeniyet University School of Medicine Istanbul, Turkey.
The uric acid dilemma: causal risk factor for hypertension and CKD or mere bystander? Mehmet Kanbay, Istanbul, Turkey Chairs: Anton H. van den Meiracker, Rotterdam, The Netherlands Claudia R.C. Van Roeyen,
More informationSummary of Research and Writing Activities In Cardiovascular Disease
Summary of Research and Writing Activities In Cardiovascular Disease Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts
More information